Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $15.8 million.

  • Madrigal Pharmaceuticals' Non-Current Assets rose 6436.09% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year increase of 5646.41%. This contributed to the annual value of $9.3 million for FY2024, which is 18536.44% up from last year.
  • Madrigal Pharmaceuticals' Non-Current Assets amounted to $15.8 million in Q3 2025, which was up 6436.09% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Non-Current Assets ranged from a high of $15.8 million in Q3 2025 and a low of $866000.0 during Q2 2023
  • In the last 5 years, Madrigal Pharmaceuticals' Non-Current Assets had a median value of $1.9 million in 2021 and averaged $4.9 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Non-Current Assets crashed by 5308.78% in 2023, and later soared by 83083.14% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Non-Current Assets (Quarter) stood at $1.6 million in 2021, then fell by 27.0% to $1.2 million in 2022, then soared by 171.49% to $3.3 million in 2023, then surged by 185.36% to $9.3 million in 2024, then skyrocketed by 69.28% to $15.8 million in 2025.
  • Its Non-Current Assets was $15.8 million in Q3 2025, compared to $12.0 million in Q2 2025 and $8.6 million in Q1 2025.